Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: A pharmacokinetic and pharmacodynamic analysis

Drug and Alcohol Dependence

Volumn 76, Issue 1, 2004, Pages 63-72

  Newcombe, David A L ^a,b   Bochner, Felix ^a,c   White, Jason M ^a,b   Somogyi, Andrew A ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Drug & Alcohol Services South Australia   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Holders; LAAM; Methadone; Non holders; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BENZODIAZEPINE; DRUG METABOLITE; LEVACETYLMETHADOL; METHADONE; MORPHINE;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BREATHING RATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG SCREENING; EXPERIENCE; FEMALE; GENDER; HEALTH PROGRAM; HUMAN; MALE; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; SCORING SYSTEM; STEADY STATE; SUBSTITUTION THERAPY; VENOUS BLOOD; WITHDRAWAL SYNDROME;

ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; METHADONE; METHADYL ACETATE; MIDDLE AGED; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 5444262417     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2004.04.004     Document Type: Article

References (41)

1. Anonymous, April 2001. FDA warns about Orlaam T01-15. Print Media 301-827-6242.
2. Anonymous, April 2001. EMEA public statement on the recommendations to suspend the marketing authorisation for ORLAAM (Levoacetylmethadol) in the European Union. The European Agency for the Evaluation of Medicinal Products.
3. Ball, J.C., Ross, A., 1991. The Effectiveness of Methadone Maintenance Treatment; Patients, Programs, Services, and Outcome. Springer-Verlag, New York.
4. Bell J., Mattick R., Hay A., Chan J., Hall W. Methadone maintenance and drug-related crime. J. Subst. Abuse. 9:1997;15-25
5. Billings R.E., Booher R., Smits S., Pohland A., McMahon R.E. Metabolism of acetylmethadol. A sensitive assay for noracetylmethadol and the identification of a new active metabolite. J. Med. Chem. 16:1973;305-306
6. Billings R.E., McMahon R.E., Blake D.A. l-Acetylmethadol (LAM) treatment of opiate dependence: plasma and urine levels of two pharmacologically active metabolites. Life Sci. 14:1974;1437-1446
7. Capelhorn J.R.M., Bell J., Kleinbaum D.G., Gebski V.J. Methadone dose and heroin use during maintenance treatment. Addiction. 88:1993;119-124
8. Deamer R.L., Wilson D.R., Clark D.S., Prichard J.G. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J. Addict. Dis. 20(4):2001;7-14
9. Doverty M., Somogyi A.A., White J.M., Bochner F., Beare C.H., Menelaou A., Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 93:2001;155-163
10. Dyer K.R., White J.M. Patterns of symptom complaints in methadone maintenance patients. Addiction. 92:1997;1445-1455
11. Dyer K.R., Foster D.J., White J.M., Somogyi A.A., Menelaou A., Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of holders versus non-holders and concentration-effect relationships. Clin. Pharmacol. Ther. 65:1999;685-694
12. Dyer K.R., White J.M., Foster D.J.R., Somogyi A.A. The relationship between mood state and plasma methadone concentration in maintenance patients. J. Clin. Psychopharmacol. 21:2001;78-84
13. Eap C.B., Bourquin M., Martin J., Spagnoli J., Livoti S., Powell K., Baumann P., Deglon J. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 61:2000;47-54
14. Eissenberg T., Stitzer M.L., Bigelow G.E., Buchhalter A.R., Walsh S.L. Relative potency of levo-α-acetylmethadol and methadone in humans under acute dosing conditions. J. Pharmacol. Exp. Ther. 289:1999;936-945
15. Finkle B.S., Jennison T.A., Chinn D.M., Ling W., Holmes E.D. Plasma and urine disposition of 1-alpha-acetylmethadol and its principal metabolites in man. J. Anal. Toxicol. 6:1982;100-105
16. Foster D.J., Somogyi A.A., Dyer K.R., White J.M., Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br. J. Clin. Pharmacol. 50:2000;427-440
17. Fudala P.J., Vocci F., Montgomery A., Trachtenberg A.I. Levomethadyl acetate (LAAM) for the treatment of opioid dependence; a multisite, open-label study of LAAM safety and an evaluation of the product labeling and treatment regulations. J. Maintenance Addictions. 1:1997;9-39
18. Grønbladh L., Ohlund L.S., Gunne L.M. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr. Scand. 82:1990;223-227
19. Harris, S., Hawken, L., Bell, J., et al., 2000. Investigating methadone withdrawal using buprenorphine: findings of a multisite pilot study. In: Proceedings of the Combined Australian Professional Society on Alcohol and Drugs and National Methadone Conference.
20. Henderson G.L., Wilson B.K., Lau D.H. Plasma l-alpha-acetylmethadol (LAAM) after acute and chronic administration. Clin. Pharmacol. Ther. 21:1977;16-25
21. Holmstrand J., Anggård E., Gunne L.M. Methadone maintenance: plasma levels and therapeutic outcome. Clin. Pharmacol. Ther. 23:1978;175-180
22. Horng J.S., Smits S.E., Wong D.T. The binding of the optical isomers of methadone, alpha-methadol, alpha-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res. Commun. Chem. Pathol. Pharmacol. 14:1976;621-629
23. Huber A., Ling W., Fradis J., Charuvastra V.C. Comparison of the effects of methadone and LAAM on the electrocardiogram. Paper presented at the 63rd Annual CPDD Scientific Meeting. Drug Alcohol. Depend. 63(Suppl. 1):2001;S70
24. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New Engl. J. Med. 343:2000;1290-1297
25. Kaiko R.F., Inturrisi C.E. Disposition of acetylmethadol in relation to pharmacologic action. Clin. Pharmacol. Ther. 18:1975;96-103
26. + currents. J. Pharmacol. Exp. Ther. 303:2002;688-694
27. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., Mehler P.S. Torsades de Pointes associated with very-high-dose methadone. Ann. Inter. Med. 137:2002;501-504
28. Kreek M.J. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. N.Y. Acad. Sci. 909:2000;186-216
29. Ling W., Klett J.C., Gillis R.D. A cooperative clinical study of methadyl acetate. 1 Three-times-a-week regimen. Arch. Gen. Psychiatry. 35:1978;345-353
30. Ling W., Rawson R.A., Compton M.A. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J. Psychoactive Drugs. 26:1994;119-128
31. McMahon R.E., Culp H.W., Marshall F.J. The metabolism of alpha-DL-acetylmethadol in the rat: identification of the probable active metabolite. J. Pharmacol. Exp. Ther. 149:1965;436-445
32. Menelaou, A., Brixen, M.L., Christensen, B., Somogyi, A.A., Newcombe, D., White, J., Christrup L., 1999. Simultaneous quantification of LAAM and its active metabolites in plasma and urine using HPLC with UV detection. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 167.
33. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J. Acquir. Immune. Defic. Syndr. 6:1993;1953-1959
34. Nickander R., Booher R., Miles H. Alpha-l-acetylmethadol and its N-demethylated metabolites have potent opiate action in the isolated guinea pig ileum. Life Sci. 14:1974;2011-2017
35. Nilsson M.I., Anggård E., Holmstrand J., Gunne L.M. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur. J. Clin. Pharmacol. 22:1982;343-349
36. Ritter A.J., Lintzeris N., Clark N., Kutin J.J., Bammer G., Panjari M. A randomised trial comparing levo-alpha-acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction. 98:2003;1605-1613
37. Smits S. The analgesic activity of alpha-l-acetylmethadol and two of its metabolites in mice. Res. Commun. Chem. Path. Pharmacol. 8:1974;575-578
38. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Dose-response effects of methadone in the treatment of opioid dependence. Ann. Inter. Med. 199:1993;23-27
39. Tennant F.S., Rawson R.A., Pumphrey E., Seecof R. Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). J. Subst. Abuse Treat. 3:1986;195-202
40. Umans J.G., Inturrisi C. Analgesic activity of methadone, l-alpha-acetylmethaodol and its normetabolites after intracerebroventricular administration to mice. Res. Commun. Subst. Abuse. 2:1981;291-302
41. Ward J., Hall W., Mattick R.P. Role of maintenance treatment in opioid dependence. Lancet. 353:1999;221-226